News & Analysis on Clinical Trial Services & Contract Research And Development
People on the Move
By Fiona BARRY
- Last updated on
Adaptimmune, a biotech concentrated on T-cell therapies, has appointed Rafael Amado Chief Medical Officer (pictured), and Adrian Rawcliffe as Chief Financial Officer. Both appointments will take effect next Monday.
Amado will assume responsibility for the company’s clinical trials in the US and Europe under its strategic collaboration with GlaxoSmithKline (GSK).
He will also lead the company’s R&D pipelines. Before Adaptimmune, Amado was Senior VP and Head of Oncology R&D at GSK. He has also worked at Amgen, as Executive Director of Therapeutic Oncology. His special interest lies in biological characterization of tumours for patient selection, which he applied to targeted drug development with anti-EGFR agents in colorectal cancer.
Rawcliffe will manage Adaptimmune’s finances and operations, including compliance and risk management. He joins from GSK where he was Senior VP, Finance for North America. Previously he held several senior finance and business development roles at GSK, including Senior VP, Worldwide Business Development and R&D Finance.